A recent study published in the Journal of Nuclear Medicine highlights the development and efficacy of a novel PET imaging agent, 68Ga-FZ-NR-1, specifically targeting Nectin-4 in triple-negative breast cancer (TNBC). This subtype of breast cancer, associated with a high rate of recurrence and low five-year survival rates, lacks effective targeted imaging tools. Researchers at Fudan University Shanghai Cancer Center demonstrated that 68Ga-FZ-NR-1 PET/CT not only identified tumors with greater precision compared to conventional imaging but also matched biopsy results confirming high Nectin-4 expression in identified lesions. The findings indicate potential improvements in diagnosing and treating TNBC and could lead to advancements in nuclear medicine for other types of cancers. Additionally, a separate study revealed that a new PET tracer, 89Zr-DFO-girentuximab, effectively detects clear cell renal cell carcinoma, further showcasing the promising developments in cancer imaging.
Thu, 13 Mar 2025 12:14:44 GMT | healthcare-in-europe.com